Literature DB >> 21312035

Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma.

G Garcea1, N Ladwa, C P Neal, M S Metcalfe, A R Dennison, D P Berry.   

Abstract

BACKGROUND: Serological proinflammatory markers such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been associated with reduced survival for many different types of cancer. This study determined the prognostic value of the preoperative value of these markers in patients with resectable pancreatic adenocarcinoma.
METHODS: Consecutive patients who underwent pancreaticoduodenectomy for pancreatic ductal adenocarcinoma were entered into our database from 2001 to the present day. CRP, NLR, and PLR at the time of presentation were recorded as well as overall and disease-free survival.
RESULTS: Seventy-four patients were identified. Overall median survival was 35.0 months and median disease-free survival was 27.0 months. Follow-up ranged from 1 to 125.8 months. Preoperative NLR was significantly greater in those patients who developed recurrence in the follow-up period (4.5 vs. 3.1). CRP and PLR were not found to differ significantly between the two groups. Kaplan-Meier survival analysis of patients with NLR > 5 demonstrated a disease-free survival of 12 months compared with 52 months for those patients with NLR < 5 (p < 0.001).
CONCLUSION: Preoperative NLR offers important prognostic information regarding disease-free survival following curative resection of pancreatic ductal adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21312035     DOI: 10.1007/s00268-011-0984-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  18 in total

1.  Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.

Authors:  Xin An; Pei-Rong Ding; Yu-Hong Li; Feng-Hua Wang; Yan-Xia Shi; Zhi-Qiang Wang; You-Jian He; Rui-Hua Xu; Wen-Qi Jiang
Journal:  Biomarkers       Date:  2010-09       Impact factor: 2.658

2.  Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio.

Authors:  Imran Bhatti; Oliver Peacock; Gareth Lloyd; Michael Larvin; Richard I Hall
Journal:  Am J Surg       Date:  2010-02-01       Impact factor: 2.565

3.  Fish oil-enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer.

Authors:  M D Barber; J A Ross; T Preston; A Shenkin; K C Fearon
Journal:  J Nutr       Date:  1999-06       Impact factor: 4.798

Review 4.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

5.  The association of pre-treatment peripheral blood markers with survival in patients with pancreatic cancer.

Authors:  Mehmet Aliustaoglu; Ahmet Bilici; Mesut Seker; Faysal Dane; Murat Gocun; Volkan Konya; Bala Basak Oven Ustaalioglu; Mahmut Gumus
Journal:  Hepatogastroenterology       Date:  2010 May-Jun

6.  Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer.

Authors:  Paul Glen; Nigel B Jamieson; Donald C McMillan; Ross Carter; Clem W Imrie; Colin J McKay
Journal:  Pancreatology       Date:  2006-07-13       Impact factor: 3.996

7.  Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.

Authors:  Michael W Müller; Helmut Friess; Jörg Köninger; David Martin; Moritz N Wente; Ulf Hinz; Güralp O Ceyhan; Pavel Blaha; Jörg Kleeff; Markus W Büchler
Journal:  Am J Surg       Date:  2008-02       Impact factor: 2.565

8.  Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio.

Authors:  Richard A Smith; Paula Ghaneh; Robert Sutton; Michael Raraty; Fiona Campbell; John P Neoptolemos
Journal:  J Gastrointest Surg       Date:  2008-06-10       Impact factor: 3.452

9.  Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas.

Authors:  J K Pine; K G Fusai; R Young; D Sharma; B R Davidson; K V Menon; S H Rahman
Journal:  Eur J Surg Oncol       Date:  2009-01-06       Impact factor: 4.424

10.  Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response.

Authors:  Bobby Tingstedt; Patrik Johansson; Bodil Andersson; Roland Andersson
Journal:  Scand J Gastroenterol       Date:  2007-06       Impact factor: 2.423

View more
  78 in total

1.  Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy.

Authors:  Shun-Jun Fu; Shun-Li Shen; Shao-Qiang Li; Yun-Peng Hua; Wen-Jie Hu; Li-Jian Liang; Bao-Gang Peng
Journal:  Med Oncol       Date:  2013-09-13       Impact factor: 3.064

2.  Prognostic significance of preoperative fibrinogen in patients with colon cancer.

Authors:  Zhen-Qiang Sun; Xiao-Na Han; Hai-Jiang Wang; Yong Tang; Ze-Liang Zhao; Yan-Li Qu; Rui-Wei Xu; Yan-Yan Liu; Xian-Bo Yu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

3.  Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients.

Authors:  Wei-wei Zhang; Ke-jun Liu; Guo-lin Hu; Wei-jiang Liang
Journal:  Tumour Biol       Date:  2015-06-11

4.  Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.

Authors:  Hiroyuki Asama; Rei Suzuki; Tadayuki Takagi; Mitsuru Sugimoto; Naoki Konno; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Mika Takasumi; Yuki Sato; Hiroki Irie; Takuto Hikichi; Hiromasa Ohira
Journal:  Mol Clin Oncol       Date:  2018-08-10

5.  Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.

Authors:  Traian Dumitrascu; Dragos Chirita; Mihnea Ionescu; Irinel Popescu
Journal:  J Gastrointest Surg       Date:  2013-01-15       Impact factor: 3.452

6.  Prognostic Significance of the Immunological Indices in Patients Who Underwent Complete Resection of Pulmonary Metastases of Colorectal Cancer.

Authors:  Yuki Okazaki; Masatsune Shibutani; E N Wang; Hisashi Nagahara; Tatsunari Fukuoka; Yasuhito Iseki; Shinichiro Kashiwagi; Hiroaki Tanaka; Kiyoshi Maeda; Kosei Hirakawa; Masaichi Ohira
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

7.  Prognostic Scoring System for Patients Who Present with a Gastric Outlet Obstruction Caused by Advanced Pancreatic Adenocarcinoma.

Authors:  Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Ryo Ashida; Yukio Yoshida; Masaki Tanaka; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

8.  Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Eiji Noda; Hiroshi Ohtani; Yukio Nishiguchi; Kosei Hirakawa
Journal:  Surg Today       Date:  2014-05-10       Impact factor: 2.549

9.  Low total lymphocyte count is associated with poor survival in patients with resected pancreatic adenocarcinoma receiving a GM-CSF secreting pancreatic tumor vaccine.

Authors:  Aaron J Schueneman; Elizabeth A Sugar; Jennifer Uram; Elaine Bigelow; Joseph M Herman; Barish H Edil; Elizabeth M Jaffee; Lei Zheng; Daniel A Laheru
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

10.  Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.

Authors:  Evan S Glazer; Omar M Rashid; Jose M Pimiento; Pamela J Hodul; Mokenge P Malafa
Journal:  Surgery       Date:  2016-07-20       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.